Hanchung Medical Strengthens Global Aesthetic Leadership at ‘KIMES 2026,’ Unveiling New Products ‘Celestella’ and ‘Celexo’

March 2026 - Seoul, Korea

Hanchung Medical announced its participation in the 2026 Korea International Medical & Hospital Equipment Show (KIMES 2026), held this past March at COEX in Seoul. During the event, the company identified the latest technology trends in the medical and beauty industries and introduced its next-generation flagship products, ‘Celestella’ and ‘Celexo.’

KIMES is an international business platform where innovative products from the global medical device and aesthetic markets converge. This year, leading domestic and international companies showcased diverse industry trends, ranging from AI-integrated medical devices to cutting-edge aesthetic equipment. Through this visit, Hanchung Medical established distribution strategies aligned with the rapidly evolving smart healthcare environment and further solidified partnerships with global buyers.

Hanchung Medical drew significant attention by placing its new products, ‘Celestella’ and ‘Celexo,’ at the forefront of its exhibition activities:

  • Celestella: An HA filler featuring a high-capacity configuration of 10 syringes per box. It received high praise from industry professionals for its cost-effectiveness and premium quality, driven by enhanced user convenience and a stable supply system.

  • Celexo: A high-concentration exosome solution positioned as Hanchung Medical’s next-generation lineup for the skin booster market. Utilizing advanced exosome technology—a key trend in the aesthetic industry—it targets the skin regeneration and anti-aging sectors.

Numerous overseas buyers who encountered the products on-site expressed strong interest in Hanchung Medical’s unique product configurations and reliable distribution system, leading to in-depth discussions regarding future collaborations.

“Our participation in KIMES, Korea's largest medical device exhibition, allowed us to precisely gauge the demands of the global aesthetic market,” said an official from Hanchung Medical. “With the high-capacity Celestella and the technologically innovative Celexo leading the way, we will continue to grow as a specialized distribution company that connects the Korean and global markets while meeting the diverse needs of our international clientele.”